When examining instances of negative FFR paired with positive non-hyperemicresults—a trend more evident in the GFR-L group—two key risk-enhancingfactors surfaced for this cohort: insulin-treated diabetes (elevating risk over11 times) and COPD (enhancing risk five-fold). This evidence concerns the gene INS and diabetes mellitus.